


NATIONAL TUBERCULOSIS, LEPROSY & LUNG DISEASE PROGRAM CATEGORY IV DR TB - 03 FACILITY REGISTER





NATIONAL TUBERCULOSIS, LEPROSY & LUNG DISEASE PROGRAM CATEGORY IV DR TB - 03 FACILITY REGISTER



February 2023 MOH/REG/DNTLDP/05

Revised case Definitions

A bacteriologically confirmed TB case-has a positive specimen by smear microscopy, cculture, Xpert MTB/RIF,Truenat,LF Lam or Lamp.

A **clinically diagnosed** TB Case is one who does not fulfill the criteria for bacteriological confirmation but has been diagnosed with active TB by a Clinician who has decided to give the patient a full course of TB treatment. Clinically diagnosed cases found to be bacteriologically positive (before or after starting treatment) should be reclassified as bacteriologically confirmed.

Definitions

- 1. **Monoresistance (MR):** resistance to one first-line anti-TB drug only.
- 2. **Rifampicin resistance (RR TB):** resistance to Rifampicin detected using phenotypic or genotypic methods.
- 3. **Polydrug resistance (PDR TB):** resistance to more than one first-line anti-TB drug (other than both Isoniazid and Rifampicin).
- 4. **Multidrug resistance (MDR TB):** resistance to both Isoniazid and Rifampicin with or without resistance to other first-line drugs.
- 5. **Pre-XDRTB**: fulfils the definition of multidrug resistant and rifampicin resistant TB (MDR/RRTB) and which are also resistant to any fluoroquinolone
- 6. **Extensively drug resistance (XDR TB):** fulfills the definition of MDR/RR TB and also resistant to any Fluoroquinolone and at least one additional group A drugs (Bedaquiline,and Linezolid)

	Classification of Category IV TB Patients
New (N)	Patients who have never received anti-tuberculosis treatment, or who have received anti-tuberculosis treatment for less than one month. (Note: patients who had DST at the start or within one month of a WHO regimen and are then switched to a second line regimen because of resistance are placed in this group, even if they received more than one month of Category I treatment).
Relapse (R)	Patients previously treated for tuberculosis that has been declared cured or treatment completed, and then diagnosed with MDR-TB.
Return after loss to follow up	Patients who return to treatment with confirmed MDR-TB after interruption of treatment for two months or more
After failure of First Line Treatment (FFT)	Patients who return after having failed the first treatment i.e smear positive at earliest, month 5
After failure of Retreatment (FRT).	Patients who return after having failed the re-treatment regimen.
Transfer in (TI)	Patients who have been transferred from another register for treatment of drug- resistant TB to second line treatment. Their outcomes should be reported to the transferring unit so that it can report their outcomes in the cohort in which they originally started MDR-TB treatment.

Outcomes	Definition
Treatment Completed (TC)	DRTB patient who has completed Treatment as recommended Without evidence of failure BUT no record that three or more Consecutive cultures taken at least 30 days apart are negative after the intensive phase.
Cured (C)	DRTB patient who completes treatment with three or more consecutive negative cultures taken at least 30 days apart after the intensive phase.
Loss to Follow Ups (LTFU)	A patient who interrupts DR-TB treatment for two or more consecutive Months.
Treatment failure (F)	Treatment terminated or need for permanent regimen change of at Least two anti-TB drugs because of: • Lack of conversion by the end of the intensive phase; or • Bacteriological reversion in the continuation phase after conversion to negative • Evidence of additional acquired resistance to fluoroquinolones or Second-line injectable drugs; or • Adverse drug reactions
Dead (D)	A patient who dies from any cause while on DR-TB treatment.
Not evaluated (NE)	A patient for whom no treatment outcome assigned. (This includes cases "transferred out" to another treatment unit and whose treatment outcome is unknown).

CATEGORY IV REGISTER

	ation No.				No./Passport No	er		onth(s)	tration	ration	e/BMI for age	Place of	ecify)	/EP)	site	ent into regist	son for ering DR-TB ter (tick priately)	Ti	Gene (pert ruen Key 3	/ at			(Enter regist pend know	r the tered ing it n. See R=Re	DST tas a shoule treat	ug su that re categ Id be f atment ant, S=	esulted ory IV illed in card	d in the patien when for fu	e pati nt. If t n the r Il histo	ent b he DS esults ory of	eing ST is s are DST			or DRTB before? Yes/No	tre	DR-TB atmen	,₊ t	Start of reatment month 0	-	lonth 1		onth 2	Mon 3	
ON Trivo	Sub County Registration No.	Date of Registration	Name in full (Three names)	Sex (M/F)	National ID Number/NEMIS No./Passport No	NHIF Number	Date of Birth (dd/mm/yyyy)	Age - Year(s)/Month(s)	Weight at Registration	ıt at	BMI/Z score/BMI	residence Mobile No (Patient & Treatment supporter)	Occupation (specify)		EPTB Specify	Bacteriologically confirmed	Clinically Diagnosed	Date sample collected	Date results received	Results	Registration group (key 1)	Resistance Pattern (key 2)	R F	ł Z	E	Fq	Cfz	Bdq	Lzd	Pretomanide	Others specify	Date sample taken for DST	Date DST results received	Has the patient ever been treated for DRTB before? Yes/No	Initial Regimen and Start Date	Modified Regimen (in drug initials)	Date started	Smear	Smear	Culture	Smear	Culture	Smear key 6	Culture key 7
																																						,						
																																							<u> </u>	<u> </u>	_			
	-									_	$\frac{1}{1}$											\dashv															_		+					
																																							+					
										_	\perp				_							\perp																						

	Key 1 - Registration Group
N	New
R	Relapse
LTFU	Loss to follow-up
FFT	After failure of first treatment with first line drugs
FRT	After failure of treatment with first line drugs
TI	Treatment in
0	Other

Ke	y 2 - Resistance Patterns								
MDR	Multi drug resistant TB								
PRE XDR	Pre-Extensively drug resistance TB								
XDR	Extensively drug resistance TB								
PDR	Poly drug resistant TB								
MR	Mono drug resistant TB (Except RR)								
RR	Rifampicin Mono resistant								

	Key 3 - GeneXpert Results
TS	MTB detected, rifampicin resistance not detected
RR	MTB detected, rifampicin resistance detected
TI	MTB detected, rifampicin resistance indeterminate
N	MTB not detected
I	Invalid/No results/Error

Key 4 - I	Key 4 - Nutrition support										
NC	Nutrition counselling										
RUTF	Therapeutic feed										
FBF	Supplementary feed										
Vitamin A											
Pyridoxine											
ND	Not done										

Key 5 - Z score/BM	I for age/BMI
Severely malnourished	<16 / < -3SD
Moderately malnourished	16 - 18.5 / < -2SD
Normal	18.5 -24.9 / > - 1SD
Overweight	25 - 30 / > - 2SD
Obese	>30 /> -3SD

Smear (S) and Culture (c) results during treatment

Month 4	n M	lonth 5	Month 6	Month 7		onth 8	Mont 9	- 1	10nth	_ I	onth 11	Mo 1		Moi 1		Mor 14		Mor	nth 5	Moi 10		Moi 1		Mont 18		Mon 19		Mon 20		Mon		Mont 22		onth 23		onth 24			HIV	Inforr	mati	ion					
Smear	S	Culture	Smear	Smear	Smear	Culture	Smear	Cutture	Smear	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Culture	Smear	Smear	Culture	Is the Patient Diabetic? Y/N	Other Comobidities	HIV Pos/Neg/Not Done / Declined Date	CPT Y/N,	Date	ART Y/N, N/A Date	Nutrition Support	Treatment Outcome	Date of Treatment Outcome	Comme	nts
											1																																				
																																				1											
	\perp				_																										_				_						_						\blacksquare
	+										Τ														1		<u> </u>	\top	1	\neg	+	\top				Τ											
	+	\perp																									\dashv		+						-												_
	+	\dashv			-						Τ														_	$\overline{}$	\dashv	$\overline{}$		\neg	+	\top				Т											
																											1				<u> </u>																-
	+																								\dashv		\dashv												_								

	W
0	No AAFB seen
Scanty	1-9 AFB per 100HPF
+	>10-99 AFB per 100HPF
++	>1-10 AFB in 50HPF
+++	>10 AFB in 20HPF

Key 7 - Cultu	res
Growth	G
No Growth	NG
Non tuberculous mycobacteria isolated but no growth of MTB	NG (NTM)
Contaminated	С

		Ke	y 8 - Drug Abbreviatio
GROUP A	A	GROUP	В
Lfx	Levofloxacin	Cfz	Clofazimine
Mfx	Moxifloxacin	Cs	Cycloserine
Bdq	Bedaquiline	Trd	Terizidone
Lzd	Linezolid	GROUP	С
		Dlm	Delaminid
		Pto	Prothionamide

Eto	Ethionamide
PAS	P- aminosallic Acid
Imp	Imipinem
Am	Amicacin
Km	Kanamycin
Е	Ethambutol
Z	Pyrazinamide

Key 9 - Outcome Treatment	
С	Cured
тс	Treatment Complete
D	Dead
LTFU	Lost to follow up
F	Treatment failure
NE	Not Evaluated



National Tuberculosis, Leprosy and Lung Disease Program

1 ** Floor, Afya Annex, Kenyatta National Hospital Grounds
P.O. Box 20781 - 00202 Nairobi

Email: info@nltp.co.ke

www.nltp.co.ke